PXD070915-1

PXD070915 is an original dataset announced via ProteomeXchange.

Title	Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans
Description	The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese (Federation, 2025). However, clinical data suggest that incretin-mimetics could cause a disproportionate decrease in lean body mass (LBM) (Jastreboff et al., 2022; Wilding et al., 2021), raising a concern for deterioration of skeletal muscle and acceleration of sarcopenic obesity (Prado et al., 2024). Unfortunately, muscle mass and function are not routinely assessed in obesity studies and original data on the matter remains sparse. In this work, we conducted various pre-clinical studies and a proof-of-concept clinical trial to examine how skeletal muscle is affected by AOMs. The overarching goal of our studies were to test if AOMs affect muscle mass disproportionately or whether changes are a simple function of weight loss. We found that in mice with diet-induced obesity (DIO), incretin-based therapies result predominantly in a substantial decrease in fat mass alongside a small but significant decrease in LBM. Among the lean tissues, the decrease in liver mass exceeded the change in muscle mass robustly. While absolute muscle mass did decrease, relative muscle mass (i.e., the muscle mass to body weight (BW) ratio) improved significantly. Similarly, we found that absolute muscle strength decreased mildly but increased relative to the BW of mice.
HostingRepository	PRIDE
AnnounceDate	2026-01-22
AnnouncementXML	Submission_2026-01-22_05:19:36.774.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Andreas Hentschel
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: NEWT:10090;
ModificationList	iodoacetamide derivatized residue
Instrument	Q Exactive HF

Revision	Datetime	Status	ChangeLog Entry
0	2025-11-18 15:51:48	ID requested
⏵ 1	2026-01-22 05:19:37	announced

Dataset with its publication pending

submitter keyword: Muscle

GLP-1

Incretins

Immobilization

Weight Loss

Wasting

Atrophy

Prof. Dr. Albert Sickmann
contact affiliation	Proteomics, Leibniz-Institut für analytische Wissenschaften -ISAS - e.V., Germany
contact email	albert.Sickmann@isas.de
lab head
Andreas Hentschel
contact affiliation	Leibniz Institut für Analytische Wissenschaften
contact email	andreas.hentschel@isas.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/01/PXD070915

PRIDE project URI

• PRIDE
  1. PXD070915
     1. Label: PRIDE project
     2. Name: Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans